Zydus Cadila gets USFDA nod to market generic drug to treat tapeworm infections; to manufacture product at Gujarat plant

The product will be manufactured at Zydus Cadilla's plant at Moraiya, Ahmedabad

Press Trust of India December 15, 2018 16:49:08 IST
Zydus Cadila gets USFDA nod to market generic drug to treat tapeworm infections; to manufacture product at Gujarat plant

New Delhi:  Drug firm Zydus Cadila on Saturday said it has received approval from the US health regulator to market Albendazole Tablets, used in treating certain tapeworm infections, in the American market.

The company has received the final approval from the US Food and Drug Administration (USFDA) to market Albendazole Tablets USP in strength of 200 mg, Zydus Cadila said in a statement.

Zydus Cadila gets USFDA nod to market generic drug to treat tapeworm infections to manufacture product at Gujarat plant

Representational image. Getty.

The company's product will be manufactured at Zydus group’s formulations manufacturing facility at Ahmedabad. It also received tentative approval from the USFDA for Pregabalin capsules, used to help control certain kinds of seizures, in multiple strengths ranging from 25 mg to 300 mg.

The product will be manufactured at its plant at Moraiya, Ahmedabad.

Zydus group now has 239 approvals from the USFDA and has so far filed over 340 abbreviated new drug applications (ANDAs) since the commencement of the its filing process in 2003-04.

Updated Date:

also read

COVID-19 variant Omicron spreads to more countries as world on alert
World

COVID-19 variant Omicron spreads to more countries as world on alert

New cases were confirmed Saturday in Germany and Italy, with Belgium, Israel and Hong Kong also reporting that the variant has been found in travellers

Bihar, Maharashtra among seven states where Centre will roll out Zydus Cadila's COVID-19 vaccine ZyCoV-D
India

Bihar, Maharashtra among seven states where Centre will roll out Zydus Cadila's COVID-19 vaccine ZyCoV-D

ZyCoV-D, the first DNA plasmid vaccine in the world for human use, was given emergency use authorisation by the Indian drug regulator on 20 August